



Personalized Cancer Care

18-20 May 2016, Holmenkollen Park Hotel, Oslo, Norway

Registration deadline April 1st, abstract deadline: March 14th.

See www.pccradiumhospital.org for more information

Now open for registration

What have we achieved since 2012 in risk prediction, early diagnosis, progression, and therapy?

Opening keynote

LEROY HOOD, Institute for Systems Biology, Seattle, USA

Genetic profiling of patients, prediction of risk and therapy response

BRUCE PONDER, Cancer Research UK, Cambridge Research Inst, UK

PAUL PHAROAH, Strangeways Research Lab, Cambridge, UK

Molecular profiling of tumors and metastases

ELAINE MARDIS, The Genome Inst, Washington Uni, MO, USA

ZOLTAN SZALLASI, Technical University of Denmark

CARLOS CALDAS, Cancer Research UK, Cambridge Research Inst, UK

PETER VAN LOO, Crick Center, London, UK

CHARLES M. PEROU, UNC – Chapel Hill, NC, USA

Tumor-host microenvironment interaction and metabolism

ARNOLD LEVINE, Princeton University, USA

LARRY NORTON, Memorial Sloan-Kettering Cancer Center, NY, USA

MINA BISSELL, Lawrence Berkley National Laboratory, CA, USA

MORAG PARK, McGill University, Montreal, Canada

Targeted therapy

GORDON MILLS, MD Andersson Cancer Center, TX, USA

RENE BERNARDS, The Netherlands Cancer Institute, The Netherlands

JOE GRAY, Oregon Health & Science University, OR, USA

ALBERTO BARDELLI, University of Torino, Italy

SOLDANO FERRONE, Mass General Hosp, Harvard, MA, USA

Translation

OLLI KALLIONIEMI, FIMM, Helsinki, Finland

LAURA VAN'T VEER, University of California, CA, USA

PER EYSTEIN LØNNING, University of Bergen, Norway

ANNE-LISE BØRRESEN-DALE, Oslo Univ Hospital, Norway

Impact of social and ethical issues on personalized medicine

DAVID LIVINGSTONE, Dana-Farber Cancer Inst, MA, USA

SERENA NIK-ZAINAL, Sanger Center, Cambridge, UK

Opening and closing remarks

ENRICO MIHICH

HANS-P. HUBER

A.-L. BØRRESEN-DALE

KURT S. ZÄNKER

